| 1109P Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study L Si, X Zhang, Y Shu, H Pan, D Wu, J Liu, L Mao, X Wang, X Wen, Y Gu, ... Annals of Oncology 34, S668-S669, 2023 | | 2023 |
| Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof BH Moreno, N Ibrahim, RF Perini, SJ Diede, SW Ebbinghaus, RA Altura US Patent App. 17/801,409, 2023 | | 2023 |
| Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody RA Altura, M Cai, SJ Diede, JA Healy, BH Moreno, N Ibrahim, ... US Patent App. 17/801,454, 2023 | | 2023 |
| Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma JA Chesney, A Ribas, GV Long, JM Kirkwood, R Dummer, I Puzanov, ... Journal of Clinical Oncology 41 (3), 528-540, 2023 | 53 | 2023 |
| Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor … A Arance, L De La Cruz-Merino, TM Petrella, R Jamal, L Ny, A Carneiro, ... Journal of Clinical Oncology 41 (1), 75-85, 2023 | 38 | 2023 |
| Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review XL Tan, A Le, H Tang, M Brown, E Scherrer, J Han, R Jiang, SJ Diede, ... Cancers 14 (24), 6108, 2022 | 1 | 2022 |
| Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases XL Tan, A Le, E Scherrer, H Tang, N Kiehl, J Han, R Jiang, SJ Diede, ... Frontiers in Oncology 12, 1025664, 2022 | | 2022 |
| Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study L Si, X Zhang, Y Shu, H Pan, D Wu, J Liu, L Mao, X Wang, X Wen, Y Gu, ... Frontiers in Immunology 13, 882471, 2022 | 5 | 2022 |
| Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3. A Ribas, PF Ferrucci, V Atkinson, R Stephens, GV Long, DP Lawrence, ... Journal of Clinical Oncology 40 (16_suppl), 9516-9516, 2022 | 7 | 2022 |
| Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma. IM Svane, SM Nair, I Puzanov, C Robert, JC Hassel, S Sandhu, ... Journal of Clinical Oncology 40 (16_suppl), TPS9589-TPS9589, 2022 | | 2022 |
| Current treatment approaches and global consensus guidelines for brain metastases in melanoma XL Tan, A Le, FC Lam, E Scherrer, RG Kerr, AC Lau, J Han, R Jiang, ... Frontiers in Oncology 12, 885472, 2022 | 9 | 2022 |
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ... The Lancet 399 (10336), 1718-1729, 2022 | 228 | 2022 |
| Long-term follow-up of KEYNOTE-029 1B and 1C: Standard-dose pembrolizumab (pembro)+ alternate-dose ipilimumab (ipi) in advanced melanoma GV Long, VF Atkinson, AM Menzies, A Diab, A Hill, C Robert, MO Butler, ... | | 2022 |
| KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation M Maio, MS Carlino, AM Joshua, E McWhirter, A Ribas, PA Ascierto, ... European Journal of Cancer 160, 1-11, 2022 | 4 | 2022 |
| LEAP-004: updated data for lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progressive disease on a prior PD-(L) 1 inhibitor GV Long, L de la Cruz-Merino, TM Petrella, R Jamal, L Ny, A Carneiro, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 17, 66-67, 2021 | | 2021 |
| KEYMAKER-U02: Investigational agents with or without pembrolizumab or pembrolizumab alone in melanoma GV Long, R Dummer, AC Pavlick, MA Postow, A Ribas, C Robert, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 17, 202-202, 2021 | | 2021 |
| Pembrolizumab in Pediatric Patients with Relapsed or Refractory Classical Hodgkin Lymphoma in Keynote-051: Response by 2007 Revised Response Criteria for Lymphoma and 2014 … B Geoerger, A Pappo, HJ Kang, ME Macy, S Dubois, T Watt, C Rossig, ... PEDIATRIC BLOOD & CANCER 68, S206-S207, 2021 | | 2021 |
| 383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody … P Fernandez-Penas, M Carlino, K Tsai, V Atkinson, M Shaheen, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 4 | 2021 |
| Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006 O Hamid, C Robert, A Daud, MS Carlino, TC Mitchell, P Hersey, ... European Journal of Cancer 157, 391-402, 2021 | 11 | 2021 |
| 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) A Ribas, J Chesney, GV Long, JM Kirkwood, R Dummer, I Puzanov, ... Annals of Oncology 32, S868-S869, 2021 | 36 | 2021 |
